CURASEPT ADS | DNA ASTRINGENT PRO ORAL RINSE

Chlorhexidine Digluconate 0,20% with ADS NEW + Hamamelis Virginiana + DNA/RNA

Format: 200 ml

Rapidly reduces gum bleeding thanks to the astringent effect of Hamamelis Virginiana while the anti-plaque activity of Chlorhexidine effectively counteracts bacterial plaque, the main cause of the problem.
Indicated in case of easily bleeding, swollen and edematous gums, in case of bleeding during home brushing, even after dental sessions.
Ideal for 7-14 days.

Related products

CURASEPT ADS | DNA ASTRINGENT PRO GEL

CURASEPT ADS | DNA ASTRINGENT PRO TOOTHPASTE

Curasept Softline maxi soft 010 toothbrush and blister

CURASEPT SOFTLINE MAXI SOFT TOOTHBRUSH 010

shock action mousse home and pack Curasept Biosmalto Caries Abrasion Erosion mint and strawberry flavors

CURASEPT SOFTLINE TOOTHBRUSH EXTRA SOFT 012

Accessibility Adjustments

Select your accessibility profile

Vision Impaired Mode

Enhances website's visuals

Seizure Safe Profile

Clear flashes & reduces color

ADHD Friendly Mode

Focused browsing, distraction-free

Blindness Mode

Reduces distractions, improves focus

Epilepsy Safe Mode

Dims colors and stops blinking

Content

Colors

Orientation

Quality Policy

The Quality for CURASEPT S.p.A. is an essential condition to put itself successfully on the market, considering its characteristics and evolution.

The development of the Company and its profit are insured by the continuous search for quality towards excellence through the continuous improvement of its processes and the search for partners with quality systems adapted to our standards.

The Company aims to increase the customer satisfaction through the application of its Quality Management System, including the processes to improve the system and to ensure the compliance with the customer and applicable regulatory requirements.

For this purpose, the Company performs specific risks and opportunities assessment activities, connected to the context, stakeholders and related objectives, in order to identify the areas of system improvements and to define the appropriate actions for the risk control and mitigation and strengthening of its Quality System.

The starting point for the implementation of this policy is the pursuit of the following objectives:

Define and implement a Quality Management System according to 9001:2015+A1:2024 e UNI CEI EN ISO 13485:2021 regulation, as Manufacturer of Medical Devices;
Define and implement a system of procedures and operating instructions in harmony with the Directive 93/42/CEE, the Regulation (UE) 2017/745 and the Regulation (UE) 2023/607 for the applicable parts and subsequent changes and integrations, which satisfy the essential requirements set out in Annex I;
Define and implement a system of procedures in harmony with the Directive 2010/84, the Regulation 1235/2010, the Implementation Regulation n. 520/2012 and in accordance with the objectives of “module I – “Good Vigilance Practices” (GVP);
Establish and formalize the business organizational structure with the subdivision into areas of competences;
Clarify roles and responsibilities of business functions;
Define strategies and objectives and assign human and material resources for their achievement;
Define accurately business processes and related performance factors;
Ensure compliance with qualitative, quantitative and temporal requirements;
Constantly monitor the level of adequacy of the system with reference to regulations and laws;
Promote initiatives in order to improve the process of motivational and professional growth of human resources, considered as critical resources for future business developments;
Ensure the commitment to the satisfaction of requirements and the maintenance of effectiveness of the Quality Management System.

These objectives can be realized thanks to the involvement of the whole Company personnel.

In particular, the Managers of each Function provide their contribution so that the suggested improvements can be proposed to the General Direction, so that the Quality Policy can be a priority element in the choice of business qualitative and organizational strategies.

The involvement of the whole personnel in the improvement of internal and external processes should be aimed at reducing non-compliance and internal and external costs of non-quality; for this reason all employees should feel themselves committed in pursuing this policy.

Training courses, for all business levels, are promoted and planned by the General Direction in order to keep the personnel constantly up to date on the improvements performed for the processes.

The Quality Manual, which is distributed via the SistemaQualità to all process managers and the General Director, should represent a work tool for all Managers and their personnel for the implementation of the Quality Policy.

April 2025

General Direction

CURASEPT ADS | DNA ASTRINGENT PRO ORAL RINSE

Related products

Curasept S.p.A.

FOLLOW US ON

COMPANY

NEEDS

PRODUCTS

BRANDS

Accessibility Adjustments

Bigger Text

Cursor

Line Height

Letter Spacing

Readable Font

Dyslexic Font

Align Text

Text Magnifier

Highlight Links

Invert Colors

Brightness

Contrast

Grayscale

Saturation

Reading Line

Keyboard Navigation

Highlight Titles

Reading Mask

Hide Images

Highlight Al

Read Page

Mute Sounds

Stop Animations

Vuoi accedere ai contenuti Extra? Registrati o fai Login per accedere ai contenuti a te dedicati: articoli, video ,schede… e tanto altro!

CURASEPT ADS | DNA ASTRINGENT PRO ORAL RINSE

Related products

Curasept S.p.A.

FOLLOW US ON

COMPANY

NEEDS

PRODUCTS

BRANDS

Vuoi accedere ai contenuti Extra? Registrati o fai Login per accedere ai contenuti a te dedicati: articoli, video ,schede… e tanto altro!

THE FIRST NON-STAINING CHLORHEXIDINE

Quality Policy